ENTOD Pharma Appoints Dharmesh Kharwar as Non-Executive Independent Director

Kharwar’s expertise covers a wide range of areas, including development, manufacturing, and regulatory affairs.

Mumbai-based ENTOD Pharmaceuticals has announced the appointment of Dharmesh Kharwar as a non-executive independent director on its board.

With a distinguished career spanning leadership roles at FDC, Johnson & Johnson (J&J), and MSD/Merck, Kharwar brings extensive experience across various sectors, including chemical and biological therapeutics. He currently serves on the boards of both listed and private companies.

Kharwar’s expertise covers a wide range of areas, such as development, manufacturing, regulatory affairs, quality assurance, business development, intellectual property protection, and commercial leadership.

His contributions to large-scale projects, international collaborations, and market strategies have helped drive growth and innovation in the pharmaceutical industry.

In response to his appointment, Kharwar expressed his enthusiasm, stating, "I am honored to join ENTOD Pharmaceuticals, a company that has been at the forefront of patient- and physician-centric innovations for nearly five decades. I look forward to contributing to its continued success."

Nikkhil K Masurkar, CEO of ENTOD Pharmaceuticals, shared his confidence in the new appointment, noting that Mr. Kharwar’s leadership will further enhance the company’s mission of delivering high-quality, cost-effective pharmaceutical solutions while advancing research and innovation.

ENTOD Pharmaceuticals, a 47-year-old company specializing in ENT, ophthalmology, and dermatology, boasts a portfolio of over 250 products and remains committed to pioneering developments in the healthcare sector.

Stay tuned for more such updates on Digital Health News.